{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05194111",
            "orgStudyIdInfo": {
                "id": "MCC-21-18830"
            },
            "secondaryIdInfos": [
                {
                    "id": "HM20023601",
                    "type": "OTHER",
                    "domain": "Virginia Commonwealth University"
                }
            ],
            "organization": {
                "fullName": "Virginia Commonwealth University",
                "class": "OTHER"
            },
            "briefTitle": "Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan",
            "officialTitle": "Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan (Treat HF)",
            "acronym": "TREAT-HF",
            "therapeuticArea": [
                "Cardiovascular"
            ],
            "study": "treating-heart-dysfunction-related-to-cancer-therapy-with-sacubitril-valsartan"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-08-11",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-11-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-11-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-01-03",
            "studyFirstSubmitQcDate": "2022-01-03",
            "studyFirstPostDateStruct": {
                "date": "2022-01-18",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-03",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-05",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Virginia Commonwealth University",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "To determine feasibility of recruitment and tolerability of treatment with sacubitril-valsartan among adult age survivors of cancer diagnosed at or before age 39 who have stage B heart failure.",
            "detailedDescription": "The current study will test the hypothesis that among adult age survivors of cancer diagnosed at age \\< 39 years treatment of Stage B heart failure with sacubitril-valsartan is feasible and safe."
        },
        "conditionsModule": {
            "conditions": [
                "Heart Failure",
                "Heart Dysfunction"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "SUPPORTIVE_CARE",
                "maskingInfo": {
                    "masking": "SINGLE",
                    "maskingDescription": "Cardiac magnetic resonance studies will be de-identified and assigned a study number. The identification key will not be available to cardiac magnetic resonance readers so that they are blinded to treatment allocation",
                    "whoMasked": [
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 30,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Arm 1: Sacubitril-valsartan",
                    "type": "EXPERIMENTAL",
                    "description": "Sacubitril-valsartan administered orally twice daily at a maximally tolerate dose (max dose 97mg/103mg twice daily).",
                    "interventionNames": [
                        "Drug: Sacubitril-valsartan"
                    ]
                },
                {
                    "label": "Arm 2: Valsartan",
                    "type": "EXPERIMENTAL",
                    "description": "Valsartan administered orally twice daily at a maximally tolerate dose (max dose 160mg twice daily)",
                    "interventionNames": [
                        "Drug: Valsartan"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Sacubitril-valsartan",
                    "description": "Administered orally twice daily at a maximally tolerate dose (max dose 97mg/103mg twice daily).",
                    "armGroupLabels": [
                        "Arm 1: Sacubitril-valsartan"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Valsartan",
                    "description": "Administered orally twice daily at a maximally tolerate dose (max dose 160mg twice daily)",
                    "armGroupLabels": [
                        "Arm 2: Valsartan"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Determine feasibility of recruitment to this pilot trial by evaluating the eligibility requirements among adult age survivors of cancer diagnosed at or before age 39 who have stage B heart failure.",
                    "description": "Number of participants screened for the clinical trial.",
                    "timeFrame": "24 Months"
                },
                {
                    "measure": "Determine the feasibility of recruitment to this pilot trial by evaluating the eligibility requirements among adult age survivors of cancer diagnosed at or before age 39 who have stage B heart failure.",
                    "description": "Number of participants enrolled on the trial",
                    "timeFrame": "27 Months"
                },
                {
                    "measure": "Determine tolerability of treatment with sacubitril-valsartan among adult age survivors of cancer diagnosed at or before age 39 who have stage B heart failure.",
                    "description": "Number of participants that complete therapy",
                    "timeFrame": "27 Months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Evaluate early efficacy of sacubitril-valsartan in the treatment of stage B heart failure among survivors of cancer diagnosed at or before age 39.",
                    "description": "Number of deaths while on study due to cardiac event",
                    "timeFrame": "27 Months"
                },
                {
                    "measure": "Evaluate early efficacy of sacubitril-valsartan in the treatment of stage B heart failure among survivors of cancer diagnosed at or before age 39.",
                    "description": "Number of deaths while on study due to non-cardiac events",
                    "timeFrame": "90 Days"
                },
                {
                    "measure": "Evaluate early efficacy of sacubitril-valsartan in the treatment of stage B heart failure among survivors of cancer diagnosed at or before age 39.",
                    "description": "By the number of Adverse events at 30 days",
                    "timeFrame": "30 Days"
                },
                {
                    "measure": "Evaluate early efficacy of sacubitril-valsartan in the treatment of stage B heart failure among survivors of cancer diagnosed at or before age 39.",
                    "description": "By the number of Adverse events at 60 days",
                    "timeFrame": "60 Days"
                },
                {
                    "measure": "Evaluate early efficacy of sacubitril-valsartan in the treatment of stage B heart failure among survivors of cancer diagnosed at or before age 39.",
                    "description": "By the number of Adverse events at 90 days",
                    "timeFrame": "90 Days"
                },
                {
                    "measure": "Evaluate early efficacy of sacubitril-valsartan in the treatment of stage B heart failure among survivors of cancer diagnosed at or before age 39.",
                    "description": "By determining number of participants with interval change utilizing a 6-minute walk test distance",
                    "timeFrame": "90 Days"
                },
                {
                    "measure": "Evaluate early efficacy of sacubitril-valsartan in the treatment of stage B heart failure among survivors of cancer diagnosed at or before age 39.",
                    "description": "By number of participants with cardiovascular magnetic resonance imaging assessment change in cardiac fibrosis burden.",
                    "timeFrame": "90 Days"
                },
                {
                    "measure": "Evaluate early efficacy of sacubitril-valsartan in the treatment of stage B heart failure among survivors of cancer diagnosed at or before age 39.",
                    "description": "By number of participants with cardiovascular magnetic resonance imaging assessment change in microvascular perfusion.",
                    "timeFrame": "90 Days"
                },
                {
                    "measure": "Evaluate early efficacy of sacubitril-valsartan in the treatment of stage B heart failure among survivors of cancer diagnosed at or before age 39.",
                    "description": "By number of participants with cardiovascular magnetic resonance imaging assessment change in arterial stiffness/4D flow.",
                    "timeFrame": "90 Days"
                },
                {
                    "measure": "Evaluate early efficacy of sacubitril-valsartan in the treatment of stage B heart failure among survivors of cancer diagnosed at or before age 39.",
                    "description": "By number of participants with cardiovascular magnetic resonance imaging assessment change in left ventricular ejection fraction.",
                    "timeFrame": "90 Days"
                },
                {
                    "measure": "Evaluate early efficacy of sacubitril-valsartan in the treatment of stage B heart failure among survivors of cancer diagnosed at or before age 39.",
                    "description": "By number of participants with cardiovascular magnetic resonance imaging assessment change in change in left ventricular strain.",
                    "timeFrame": "90 Days"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Age \\</= 39 years old at time of cancer diagnosis\n* Clinical records adequate to determine diagnosis and treatment regimen\n* Previous anthracycline chemotherapy\n* Global longitudinal strain \\<18% and/or\n* L VEF below the institutional lower limit of normal but \\>/=40% on echocardiogram or cardiac MRI\n* No symptoms of heart failure (shortness of breath, fatigue, swelling). Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea (shortness of breath).\n\nExclusion Criteria:\n\n* -Age \\<18 years\n* Inability to obtain consent from patient or legally authorized representative\n* Active acute or chronic psychiatric illness that in the opinion of the investigator may prevent compliance with study instructions\n* Limited English or Spanish proficiency that in the opinion of the investigator may prevent understanding the content of the informed consent form or safely completing the study procedures\n* Participation in another concurrent intervention study within 30 days or treatment with an investigational drug within 5 half-lives prior to randomization\n* Greater than mild mitral or aortic valve regurgitation/stenosis known pre-cancer therapy\n* Severe kidney disease (GFR \\<30 mL/min/1.73m2)\n* Chronic hyperkalemia (\\>5mmol/L)\n* Evidence of COVID-19 within the last 60 days or recent (21 days) exposure to close personal contact with COVID-19.\n* Greater than moderate tricuspid or pulmonary valve regurgitation/stenosis known pre-cancer therapy\n* Hemodynamically significant congenital heart disease in the opinion of the investigator (not including PFO/small ASD or small VSD)\n* Greater than moderate pericardial effusion\n* Constrictive cardiomyopathy diagnosed pre-cancer therapy\n* Family history of genetic cardiomyopathy\n* Evidence of infiltrative cardiomyopathy\n* Symptomatic heart disease based on NYHA classification\n* Allergy to valsartan or sacubitril\n* Inability to complete CMR or 6-minute walk test\n* Inability to measure non-invasive blood pressure and heart rate in the ambulatory/home setting\n* Pregnant/lactating\n* History of severe hypersensitivity reactions to gadolinium-based contrast agents (will perform limited cardiac imaging without contrast)\n* Concomitant use of other ACE inhibitors or ARBs, aliskiren, NSAIDs or lithium or the inability to stop these medications for the study",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "120 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Massey Cancer Control DWG",
                    "role": "CONTACT",
                    "phone": "804-628-4916",
                    "email": "masseycpc@vcu.edu"
                },
                {
                    "name": "Massey CTO Operations Managers",
                    "role": "CONTACT",
                    "email": "ctoclinops@vcu.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Wendy Bottinor, MD",
                    "affiliation": "Virginia Commonwealth University",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Virginia Commonwealth University",
                    "status": "RECRUITING",
                    "city": "Richmond",
                    "state": "Virginia",
                    "zip": "23298",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Massey CPC DWG",
                            "role": "CONTACT",
                            "phone": "804-628-4916",
                            "email": "masseycpc@vcu.edu"
                        },
                        {
                            "name": "Massey CTO Operations Managers",
                            "role": "CONTACT",
                            "email": "ctoclinops@vcu.edu"
                        },
                        {
                            "name": "Wendy Bottinor, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.55376,
                        "lon": -77.46026
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO",
            "description": "There are no plans to make individual participant data available to other researchers at this time."
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000006333",
                    "term": "Heart Failure"
                }
            ],
            "ancestors": [
                {
                    "id": "D000006331",
                    "term": "Heart Diseases"
                },
                {
                    "id": "D000002318",
                    "term": "Cardiovascular Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M9421",
                    "name": "Heart Failure",
                    "asFound": "Heart Failure",
                    "relevance": "HIGH"
                },
                {
                    "id": "M9419",
                    "name": "Heart Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC14",
                    "name": "Heart and Blood Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000068756",
                    "term": "Valsartan"
                },
                {
                    "id": "C000549068",
                    "term": "Sacubitril and valsartan sodium hydrate drug combination"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000959",
                    "term": "Antihypertensive Agents"
                },
                {
                    "id": "D000047228",
                    "term": "Angiotensin II Type 1 Receptor Blockers"
                },
                {
                    "id": "D000057911",
                    "term": "Angiotensin Receptor Antagonists"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M301",
                    "name": "Valsartan",
                    "asFound": "Urinary",
                    "relevance": "HIGH"
                },
                {
                    "id": "M350410",
                    "name": "Sacubitril and valsartan sodium hydrate drug combination",
                    "asFound": "Squamous Cell Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4277",
                    "name": "Antihypertensive Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4132",
                    "name": "Angiotensin II",
                    "relevance": "LOW"
                },
                {
                    "id": "M289354",
                    "name": "Giapreza",
                    "relevance": "LOW"
                },
                {
                    "id": "M4135",
                    "name": "Angiotensinogen",
                    "relevance": "LOW"
                },
                {
                    "id": "M25789",
                    "name": "Angiotensin II Type 1 Receptor Blockers",
                    "relevance": "LOW"
                },
                {
                    "id": "M28916",
                    "name": "Angiotensin Receptor Antagonists",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "AnAg",
                    "name": "Antihypertensive Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "VaCoAg",
                    "name": "Vasoconstrictor Agents"
                }
            ]
        }
    },
    "hasResults": false
}